GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (FRA:R9Z) » Definitions » Asset Impairment Charge

ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) Asset Impairment Charge : €0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Asset Impairment Charge?

ImmuneOnco Biopharmaceuticals (Shanghai)'s Asset Impairment Charge for the six months ended in Jun. 2024 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00 Mil.

ImmuneOnco Biopharmaceuticals (Shanghai) Asset Impairment Charge Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Asset Impairment Charge Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend Dec21 Dec22 Dec23
Asset Impairment Charge
- - -

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Asset Impairment Charge Get a 7-Day Free Trial - - - - -

ImmuneOnco Biopharmaceuticals (Shanghai) Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

ImmuneOnco Biopharmaceuticals (Shanghai) Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (FRA:R9Z) » Definitions » Asset Impairment Charge
Comparable Companies
HKSE:02487 HKSE:01873 HKSE:02509 HKSE:02566 HKSE:02496 HKSE:02142 HKSE:01875 HKSE:06978 HKSE:02181 HKSE:03681 VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
01541:Hong Kong
Address
1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
Website
http://cn.immuneonco.com
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

ImmuneOnco Biopharmaceuticals (Shanghai) Headlines

No Headlines